It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mammalian sex determination is controlled by antagonistic gene cascades operating in embryonic undifferentiated gonads. The expression of the Y-linked gene SRY is sufficient to trigger the testicular pathway, whereas its absence in XX embryos leads to ovarian differentiation. Yet, the potential involvement of non-coding regulation in this process remains unclear. Here we show that the deletion of a single microRNA cluster, miR-17~92, induces complete primary male-to-female sex reversal in XY mice. Sry expression is delayed in XY knockout gonads, which develop as ovaries. Sertoli cell differentiation is reduced, delayed and unable to sustain testicular development. Pre-supporting cells in mutant gonads undergo a transient state of sex ambiguity which is subsequently resolved towards the ovarian fate. The miR-17~92 predicted target genes are upregulated, affecting the fine regulation of gene networks controlling gonad development. Thus, microRNAs emerge as key components for mammalian sex determination, controlling Sry expression timing and Sertoli cell differentiation.
The cluster miR-17~92 modulates the expression of genes networks and signalling pathways to ensure proper Sry expression timing and subsequent testis differentiation, an unexpected role for miRNAs in the early steps of mammalian sex determination.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Labs. 127 and A105, Centre for Biomedical Research, University of Granada, Armilla, Department of Genetics and Institute of Biotechnology, Granada, Spain (GRID:grid.4489.1) (ISNI:0000 0001 2167 8994); Max-Delbrück Center for Molecular Medicine, Epigenetics and Sex Development Group, Berlin Institute for Medical Systems Biology, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849); CSIC/UPO/JA, Centro Andaluz de Biología del Desarrollo (CABD), Seville, Spain (GRID:grid.428448.6) (ISNI:0000 0004 1806 4977)
2 Max-Delbrück Center for Molecular Medicine, Epigenetics and Sex Development Group, Berlin Institute for Medical Systems Biology, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849)
3 Labs. 127 and A105, Centre for Biomedical Research, University of Granada, Armilla, Department of Genetics and Institute of Biotechnology, Granada, Spain (GRID:grid.4489.1) (ISNI:0000 0001 2167 8994)
4 Max Planck Institute for Molecular Genetics, Research Group Development & Disease, Berlin, Germany (GRID:grid.419538.2) (ISNI:0000 0000 9071 0620)
5 Max-Delbrück Center for Molecular Medicine, Epigenetics and Sex Development Group, Berlin Institute for Medical Systems Biology, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849); CSIC/UPO/JA, Centro Andaluz de Biología del Desarrollo (CABD), Seville, Spain (GRID:grid.428448.6) (ISNI:0000 0004 1806 4977)